Login to Your Account

Deciphera gains $52M in muscle to move lead assets to next level

By Marie Powers
News Editor

Thursday, June 1, 2017

On the eve of the ASCO annual meeting in Chicago, Deciphera Pharmaceuticals LLC disclosed a $52 million series C financing to advance lead candidates DCC-2618 and DCC-3014 beyond phase I.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription